Trial Profile
Lamivudine/tenofovir disoproxil fumarate vs emtricitabine/tenofovir disoproxil fumarate, both administered with efavirenz, in antiretroviral-naive Zambian patients with HIV-1 infection.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2013
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 21 Jul 2013 New trial record
- 03 Jul 2013 Primary endpoint 'Virological-response-rate' has been met.
- 03 Jul 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.